<DOC>
	<DOC>NCT01766778</DOC>
	<brief_summary>The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians &amp; patients in the future when they consider initiating Vildagliptin and taking balance between efficacy, compliance, risk factors, convenience and medication cost.</brief_summary>
	<brief_title>Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1. Male or Female in age â‰¥18 at Visit 1 2. Type 2 diabetes mellitus (T2DM) patients on their maximum tolerated dose of Metformin for more than 3 months 3. HbA1c (glycosylated hemoglobin) at Visit 1 greater than 7.0% 4. With nearest documented record of HbA1c before Visit 1 greater than 7.0% after patient reached his/her maximum tolerated dose of Metformin Key 1. Patients with hepatic impairment, including patients with a pretreatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2.5 X the upper limit of normal at Visit 1 2. Patients with moderate or severe renal impairment or endstagerenaldisease (ESRD) on haemodialysis at the time of enrolment 3. Patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucosegalactose malabsorption 4. Pregnant women or breastfeeding women at the time of enrolment 5. Use of insulin or other oral antidiabetic drug (OAD) apart from Metformin in the past for T2DM treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>type-2 diabetes mellitus, inadequately controlled Metformin</keyword>
</DOC>